B of A Securities raises Chemed price target to $510
B of A Securities analyst Joanna Gajuk maintained a Neutral rating on Chemed and raised the price target to $510 from $450, signaling a higher valuation outlook.
*this image is generated using AI for illustrative purposes only.
B of A Securities analyst Joanna Gajuk has maintained a Neutral rating on Chemed while raising the price target to $510 from the previous $450. The revised target indicates a higher valuation potential for the NYSE-listed stock despite the unchanged stance.
Rating and Target Details
The research note highlights a specific upward revision in the price objective. Below are the key details regarding the analyst's position:
| Metric | Value |
|---|---|
| Rating | Neutral |
| Previous Price Target | $450 |
| New Price Target | $510 |
The decision to maintain a Neutral rating suggests that while the stock's expected price has increased, the overall risk-reward profile remains balanced according to the firm's analysis.
What specific factors drove the significant 13% increase in the price target despite the Neutral rating?
How might Chemed's recent operational performance influence future analyst ratings?
What are the potential risks that could prevent Chemed from reaching the new $510 price target?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
